Diabetes Publish Ahead of Print, published online December 10, 2007

TCF7L2 regulates β-cell survival and function in human pancreatic islets

Luan Shu[1], Nadine S. Sauter[1*], Fabienne T. Schulthess[1*], Aleksey V. Matveyenko[1], José Oberholzer[2] and Kathrin Maedler[1]

[1]Larry L. Hillblom Islet Research Center, Department of Medicine, UCLA, Los Angeles, CA 90024-2852; [2]Division of Transplantation, University of Illinois at Chicago, Chicago, IL 60612, USA

[*]contributed equally to the study

Running title: TCF7L2 in human pancreatic islets

Correspondence:
Kathrin Maedler, PhD
Larry L. Hillblom Islet Research Center, UCLA
Department of Medicine
900A Weyburn Place
90024-2852 Los Angeles
CA, USA
kmaedler@mednet.ucla.edu

Received for publication 21 June 2007 and accepted in revised form 29 November 2007.

ABSTRACT

Objective: Type 2 diabetes mellitus (T2DM) is characterized by impaired insulin secretion in response to increased metabolic demand. This defect in β-cell compensation seems to result from the interplay between environmental factors and genetic pre-disposition. Genome wide association studies reveal that common variants in the transcription factor TCF7L2 are associated with increased risk of T2DM. The aim of the present study was to establish if TCF7L2 plays a role in β-cell function and/or survival.

Research Design and Methods: To investigate the effects of TCFL7L2 depletion, isolated islets were exposed to TCF7L2 siRNA versus scrambled siRNA and β-cell survival and function were examined. For TCF7L2 over-expression islets were cultured in glucose concentrations of 5.5-33.3 mM and the cytokine mix IL-1β/IFN-γ with or without over-expression of TCF7L2. Subsequently, glucose stimulated insulin secretion (GSIS), β-cell apoptosis (by TUNEL assay and Western blotting for PARP and Caspase-3 cleavage) and β-cell proliferation (by Ki67 immunostaining) were analyzed.

Results: Depleting TCF7L2 by siRNA resulted in a 5.1-fold increase in β-cell apoptosis, 2.2-fold decrease in β-cell proliferation ($p<0.001$) and 2.6-fold decrease in GSIS ($p<0.01$) in human islets. Similarly, loss of TCF7L2 resulted in impaired β-cell function in mouse islets. In contrast, over-expression of TCF7L2 protected islets from glucose and cytokine induced apoptosis and impaired function.

Conclusions: TCF7L2 is required for maintaining glucose stimulated insulin secretion and β-cell survival. Changes in the level of active TCF7L2 in β-cells from carriers of at risk allele may be the reason for defective insulin secretion and progression of type 2 diabetes.

KEYWORDS. TCF7L2, islets, apoptosis, insulin secretion, T2DM

Type 2 diabetes mellitus (T2DM) is characterized by impaired insulin secretion and insulin resistance (1). T2DM manifests when insulin secretion fails to adaptively increase to increased insulin demand. This might be due to defective β-cell mass and/or impaired beta cell function (2-3). The underlying mechanisms of β-cell failure in T2DM are still unknown, but recent genome wide association studies have offered some new targets of interest.

Grant et al reported linkage between a variant of the transcription factor 7-like 2 (TCF7L2) and type 2 diabetes in Danish and US cohorts (4). This finding has been confirmed by several other genome-wide studies (4-13) and in numerous populations (13). TCF7L2 (previously known as TCF-4) is an important downstream target of the canonical WNT signaling pathway (14). It is highly expressed in most human tissues, including heart, placenta, lung, brain, liver, adipose tissue, kidney, as well as in pancreatic β-cells, but not in the skeletal muscle (10). Interestingly,TCF7L2 expression in adipose tissue is decreased in obese subjects with T2DM (10).

TCF7L2 has been implicated in glucose homeostasis through the regulation of pro-glucagon gene expression, which encodes GLP-1 in intestinal cells (15).

The SNPs in the TCF7L2 gene that show linkage with T2DM are all found in the non-coding regions (13). It is unknown if changes in TCF7L2 expression levels in pancreatic islets directly influence β-cell function or survival. Since T2DM is characterized by impaired β-cell function and increased β-cell apoptosis, we sought to establish if islet expression levels of TCF7L2 impact glucose induced insulin secretion and vulnerability to apoptosis. After manipulating levels of TCF7L2 we examined glucose induced insulin secretion by perifusion and β-cell survival after exposure to pro-apoptotic glucose concentrations and cytokines.

MATERIALS AND METHODS

Islet isolation and culture. Human islets were isolated from pancreata of five healthy organ donors at the University of Illinois at Chicago as described previously (16) and shipped to UCLA directly after isolation. Islet purity of these 5 preparations was >95%, as judged by dithizone staining. Human islets were cultured in CMRL-1066 medium containing 5.5 mM glucose and 100 U/ml penicillin, 100 μg/ml streptomycin and 10% FCS (invitrogen, Carlsbad, CA). Mouse islets were isolated using Collagenase type 4 (Worthington, Lakewood, NJ) as described before (18) and cultured in RPMI-1640 medium containing 11.1 mM glucose. In culture a glucose concentration of 11.1 mM accomplishes the lowest frequency of β-cell apoptosis in mouse islets (19-21). Human and mouse islets were pre-cultured for 24 h before the experiment and then plated on matrix-coated plates derived from bovine corneal endothelial cells (Novamed Ltd., Jerusalem, Israel) (17). For the perifusion experiment, islets were maintained in suspension. For experimental treatment of islets, medium was changed to culture medium containing 5.5, 11.1 or 33.3 mM or 5.5 mM plus 2 ng/ml recombinant human IL-1β plus 1,000 U/ml recombinant IFN-γ (R&D Systems Inc., Minneapolis, MN) for 96 hours.

RNA interference and plasmid transfection. SiRNA-Lipofectamine2000 complexes and DNA-Lipofectamine2000 complexes were prepared according to manufacturer's instructions (Liptofectamine2000; invitrogen) using 50 nM siRNA to TCF7L2 (RNAs of 21 nucleotides, designed to target human TCF7L2; Stealth Select™ RNAi, invitrogen) and scramble siRNA (Ambion, Austin, TE) or 3 μg/ml DNA of pCMV-TCF7L2 (full length TCF7L2, from the Full-Length Mammalian Gene Collection, invitrogen) or an pCMV-empty control plasmid. Islets were pre-cultured for 24 h, medium was changed to OptiMEM (invitrogen) and SiRNA-Lipofectamine2000 complexes or DNA-Lipofectamine2000 were added. After 8 h incubation, the transfection medium was aspirated and replaced by fresh culture medium with or without elevated glucose or cytokines for additional 4 days. To monitor transfection efficiency of siRNA into

the islets, we transfected fluorescein labeled non-targeted siRNA (Cell signaling, Beverly, MA) and analyzed transfection under the fluorescent microscope during for 4 days of culture.

β-cell apoptosis, replication and TCF7L2 expression. For each independent experiment, 20 islets were plated in a 3 cm culture dish and exposed to the treatment conditions as indicated above. Four dishes per treatment group were used. After washing with PBS, islets were fixed with 4% paraformaldehyde followed by permeabilisation with 0.5% Triton X-100. β-cell apoptosis was analyzed by the TUNEL technique (In Situ Cell Death Detection Kit, AP; Roche Diagnostics, Indianapolis, IN). For β-cell proliferation, an anti human Ki67 antibody was used (Zymed, San Francisco, CA), followed by detection using cy3-conjugated donkey anti-mouse antibody (Jackson, ImmunoResearch Laboratories Inc., West Grove, PA). For β-cell TCF7L2 expression, islets were incubated with anti-TCF7L2 antibody (Cell signaling, Beverly, MA), followed by detection using cy3-conjugated donkey anti-rabbit antibody (Jackson). In all experiments, islets were double/ triple stained with guinea pig anti-insulin antibody (Dako, Carpinteria, CA), followed by detection using fluorescein-conjugated donkey anti-guinea pig antibody (Jackson). Islets were embedded in glycerol gelatin (Sigma) or Vectashield mounting media (Vector Laboratories, Inc. Burlingame, CA), which visualized all cells by DAPI staining. Fluorescence was analyzed using a Leica DM6000 microscope and images acquired using Openlab software.

Western blot analysis. For Western Blot analyses, 100 islets/ dish were plated in duplicates for each independent experiment. At the end of the incubation, islets were washed in PBS and lysed as described previously (22). PVDF filters were incubated with rabbit anti-TCF7L2 (#2566), mouse anti-cleaved PARP (#9548), rabbit anti-caspase-3 (#9961), rabbit anti-actin (#4967), anti p-AKT (Serin473 #9271) (all Cell signaling), followed by incubation with horseradish-peroxidase-linked IgG peroxidase. The emitted light was captured on X-ray film after adding Immun-Star HRP Substrate (Bio-rad Laboratories, Inc.). Density of the bands was analyzed using Labworks 4.5 software (BioImaging Systems, Upland, CA).

RNA extraction and RT-PCR. Total RNA was isolated from cultured islets (100 islets/dish) as described previously (23). For quantitative analysis, we used the Light Cycler quantitative PCR system (Roche Diagnostics, Indianapolis, IN) with a commercial kit (Light Cycler-DNA Master SYBR Green I; Roche). Primers used were 5'CTACCTAGTGTGCGGGGAAC3' and 5'GCTGGTAGAGGGAGCAGATG3' (Insulin), 5'CTGGATTGGCGTTGTTTGTG3' and 5'CTACAGCACTCCACCTTGGGA3' (PDX-1), 5'GAAGGAGCGACAGCTTCATA3' and 5'GGGGGAGGCGAATCTAGTAA3' (TCF7L2) and compared to the house keeping gene 5'AGAGTCGCGCTGTAAGAAGC3' and 5'TGGTCTTGTCACTTGGCATC3' (α-Tubulin) and 5'TCACCCACACTGTGCCCATCTACGA3' and 5'CAGCGGAACCGCTCATTGCCA ATGG3' (β-actin).

Glucose-stimulated insulin secretion (GSIS), static incubation. For each independent experiment, 20 islets were plated and exposed to the treatment conditions as indicated above. Four dishes per treatment group were used. For acute insulin release, islets were washed and pre-incubated (30 min) in Krebs-Ringer bicarbonate buffer (KRB) containing 2.8 mM glucose. The KRB was then replaced by KRB containing 2.8 mM glucose for 1 h (basal), followed by additional 1 h incubation in KRB containing 16.7 mM glucose. Islets were lysed in lysis buffer and whole islet protein amount measured by BCA protein assay (Pierce, Rockford, IL). Insulin was determined using a human insulin ELISA kit (Dako, Carpinteria, CA) or a mouse insulin ELISA kit (Alpco, Windham, NH).

Islet perifusion. Human islets plated in suspension dishes (100 islets/dish in triplicates) were pre-cultured for 4 days with scrambled or TCF7L2 siRNA. 20 islets of similar size from each treatment group were

hand-picked and suspended in Bio-Gel P-2 beads (Bio-Rad, Hercules, CA) and placed in perifusion chambers as described before (24). The perifusion system (ACUSYST-S, Cellex Biosciences, Inc., Minneapolis, MN) consisted of a multichannel peristaltic pump that delivered perifusate through six parallel tubing sets via a heat exchanger and six perfusion chambers at a constant rate of 0.3 ml/min. The perifusion buffers (KRB) were preheated to 37°C, and oxygenized with 95% O_2 and 5% CO_2 and delivered to the perifusion chambers containing the human islets. Islets were perifused for 1 h with KRB containing 2.8 mM glucose (perifusate was collected during the last 30 min. every 5 min.), for 40 min. with KRB containing 16.7 mM glucose, for 30 min. with KRB containing 16.7 mM glucose plus 100 nM GLP-1 (Glucagon-like peptide 1 fragment 7-37, human, Sigma), 30 min. with KRB containing 2.8 mM glucose and for 10 min. with 20 mM KCl. The effluent was collected in 5-min (for basal and stimulated insulin secretion) and 2-min intervals (for KCl induced insulin secretion) for determination of insulin concentrations. At the end of the perifusion, islet were collected by hand-picking and extracted with 0.18N HCI in 70% ethanol for determination of insulin content. Insulin was determined using a human insulin ELISA kit (Alpco, Windham, NH).

Statistical analysis. Immunostainings were evaluated in a randomized manner by a single investigator (L.S.) who was blinded to the treatment conditions Data are presented as means +/- SE and were analyzed by paired, Student's *t* test or by analysis of variance with a Bonferroni correction for multiple group comparisons.

RESULTS

Depletion in TCF7L2 results in impaired β-cell function. We investigated localization of TCF7L2 in human islets and found its expression in human β-cells, in confirmation with two previous reports (10; 12). Triple-staining for TCF7L2, insulin and DAPI revealed that TCF7L2 is expressed in the nucleus of β-cells (Fig.1A,1). Plasmid-overexpression of TCF7L2 resulted in increased TCF7L2 expression (Fig.1A,2), whereas in islets depleted for TCF7L2 by small interfering RNA to TCF7L2 (siTCF7L2), TCF7L2 was almost undetectable by IHC (Fig.1A3).

To establish the effects of TCF7L2 on glucose mediated insulin secretion, we depleted TCF7L2 in pancreatic islets by exposure of mouse islets to three different siRNA sequences to TCF7L2 (siTCF7L2-1,-2,-3) and human islets to one siRNA (siTCF7L2-2) (or scrambled control siRNA (siScr) for 4 days. We achieved an average down-regulation of TCF7L2 mRNA expression by 58 ±10 % (Fig.1F) and 57 ±12 % protein expression in human (Fig.3E) and in mouse islets (not shown). For evaluating transfection efficiency, islets were transfected with a FITC labeled non-targeted siRNA and green fluorescence monitored over the 4-day culture period. Transfection efficiency was about 5% after 24h and 75% after 48h, which was maintained during the 4d experiment (Fig.1A4,5).

We first tested the consequence of such down-regulation on β-cell function in mouse islets. After 4-day culture period with siRNA, we performed static incubation measurement of insulin secretion in mouse and human islets. No significant changes in insulin secretion were observed at basal levels at 2.8 mM glucose. Also, a scrambled control sequence did not change basal or stimulated insulin secretion compared to untreated islets. In contrast, glucose-stimulated insulin secretion (16.7 mM glucose) was decreased in mouse islets (1.6-, 2.3-, 1.5-fold by siTCF7L2-1, -2 and –3, respectively, $p<0.05$ Fig.1B) compared to the scrambled control. This resulted in a 2.6-, 3.6-, 2.6-fold decrease in insulin stimulatory index by siTCF7L2-1, -2 and –3, respectively (Fig.1C). The same analysis was then performed in human islets. Since three different siRNA sequences showed the same results in mice, we performed the experiments in human islets with siTCF7L2-2 only. Consistent with studies in mouse islets, glucose stimulated insulin secretion was 1.5-fold decreased by siTCF7L2-2 in human islets ($p<0.05$, Fig.1D) and the stimulatory index was decreased 2.6-

fold (Fig.1E). These changes in insulin secretion were accompanied by a 54% and 69% decrease in human islet insulin and PDX-1 mRNA, respectively (Fig.1F) and a 1.4-fold decrease in islet insulin content (17.6 pmol/islet in scrambled siRNA treated islets vs. 12.8 pmol/islet in TCF7L2 siRNA treated islets, $p<0.05$, data not shown).

We also performed islet perifusion studies in human isolated islets, which had been pre-cultured for 4 days with scrambled or TCF7L2 siRNA. Consistent with our results in the static incubation studies, depletion of TCF7L2 resulted in delayed and quantitatively diminished glucose-mediated insulin secretion ($p<0.01$ at all time points, Fig.2A). Furthermore, we examined GLP-1 induced stimulation of insulin secretion in control and siTCF7L2 treated islets (Fig.2A). Depletion of TCF7L2 led to 5.4±0.2-fold ($p<0.001$) decreased ability of GLP-1 to stimulate glucose stimulated insulin secretion in human islets. Finally we examined β-cell maximal secretory capacity by exposing islets to perifusion medium containing 20 mM KCl. Average KCl induced insulin levels were 5.2-fold higher in the siScr treated islets than in the siTCF7L2 treated islets ($p<0.001$). However, the average stimulatory index from KCl over 2.8 mM glucose alone was similar in both treatment groups (2.2 in siScr and 2.3 in siTCF7L2, n.s.); suggestive of effective KCl stimulation in TCF7L2 depleted islets.

Depletion of TCF7L2 results in impaired β-cell turnover. Since β-cell apoptosis has been recognized as the underlying mechanism of β-cell destruction and consequent decrease in β-cell mass in T2DM (25), we tested if depletion of TCF7L2 would also impair β-cell survival. Indeed, exposure of human islets to two different siRNA sequences to TCF7L2 resulted in a 2.2- and 2.5-fold decrease in β-cell proliferation, analyzed by double staining for Ki67 and insulin ($p<0.001$, Fig.3A,C) and 5.1- and 3.4-fold increase in β-cell apoptosis, analyzed by double staining for TUNEL and insulin ($p<0.001$, Fig.3B,C). Since the TUNEL assay also recognizes necrosis and DNA repair, we performed western blot analysis for cleaved Caspase-3 and cleaved PARP, two of the most downstream products of apoptotic signaling. Together with a 2.4-fold down-regulation in TCF7L2 protein expression, cleaved Caspase-3 was 5.2-fold and cleaved PARP was 2.1-fold higher expressed in human islets exposed to siTCF7L2 for 4 days (Fig.3D,E). AKT is an important survival factor for β-cells. By Western Blot analysis, we measured basal AKT phosphorylation in siScramble and siTCF7L2 treated islets. After 4 day culture of human islets in 10% FCS and 5.5 mM glucose, p-AKT was maintained, but almost undetectable in the TCF7L2 depleted islets (Fig.3F).

Over-expression of TCF7L2 protects from glucotoxicity and cytokine toxicity. Since the loss of islet TCF7L2 expression resulted in significant impairment of β-cell function and survival, we tested the hypothesis, if environmental factors which contribute to β-cell failure in diabetes influence TCF7L2 expression levels and if TCF7L2 over-expression can rescue from β-cell death.

We exposed isolated mouse and human pancreatic islets to increasing glucose concentrations (5.5, 11.1, 33.3 mM) and the mixture of cytokines (2 ng/ml IL-1β+1,000 U/ml IFN-γ) and transfected with either pCMV-TCF7L2 or an empty control plasmid under the same promoter. After the 4-day culture period, we performed GSIS (Fig.4) and immunostaining for β-cell proliferation and apoptosis (Fig.5). As we and others have reported before, increased glucose levels and exposure of islets to IL-1β+IFN-γ impaired β-cell survival and function in mouse and human islets (26). Importantly, islets transfected with TCF7L2 were protected against the deleterious effects of glucose and of cytokines. The stimulatory index was 2.7-fold decreased by 33.3 mM glucose and 7.3-fold by cytokines, compared to control incubations in mouse islets at 11.1 mM alone ($p<0.01$; Fig.4A,B). TCF7L2 over-expression induced a 2.6-fold and 4-fold increase in stimulatory index at 33.3 mM glucose and in islets treated with IL-1β+IFN-γ, respectively, compared to control, protecting from the deleterious effects of both. Basal insulin secretion levels were increased by 33.3 mM

glucose and by cytokines in mouse islets (Fig.4A), possibly as an indicator of the increased β-cell apoptosis. TCF7L2 over-expression reduced such an increase significantly ($p<0.01$). Additionally, TCF7L2 increased stimulated insulin secretion in cytokine treated islets, indicating its protective effect on β-cell insulin secretion and survival.

In human islets, similar protective effects were observed. Increased glucose levels (11.1 and 33.3 mM) and the cytokine mixture IL-1β+IFNγ reduced the islet stimulatory index 3.7-, 4.7- and 3.2-fold, respectively ($p<0.01$; Fig.4C,D), compared to conditions at 5.5 mM glucose. TCF7L2 over-expression improved β-cell GSIS significantly in all conditions. Interestingly, also at 5.5 mM glucose, TCF7L2 improved stimulated insulin secretion (Fig.4C,D). We observed similar protective results of TCF7L2 over-expression, when we looked at β-cell apoptosis and proliferation. Elevated glucose concentration dose-dependently reduced β-cell proliferation (2.5-, 5.2- and 7.4-fold reduction by 11.1 and 33.3 mM glucose and by IL-1β+IFNγ, respectively, $p<0.001$, Fig.5A,C) and induced β-cell apoptosis (1.8-, 2.7-, and 1.6-fold induction by 11.1 and 33.3 mM glucose and by IL-1β+IFNγ, respectively, $p<0.001$, Fig.5B,C) in isolated human islets, compared to control incubations. This was reversed by TCF7L2 over-expression. Proliferation was 1.8-, 2.5- and 3.1-fold-fold induced (Fig.5A,C) and apoptosis 1.6-, 1.6- and 1.5-fold reduced (Fig.5B,C) by TCF7L2 at 11.1 mM and 33.3 mM glucose and at IL-1β+IFN-γ, respectively ($p<0.01$). In order to investigate how chronically elevated glucose levels and cytokines, which contribute to β-cell failure in diabetes influence TCF7L2 expression levels and to correlate levels of TCF7L2 expression with apoptosis, we performed western blot analysis from glucose/ IL-1β+IFN-γ treated human islets transfected with pCMV-TCF7L2 or an empty control plasmid. Elevated glucose and IL-1β+IFN-γ significantly down-regulated TCF7L2 protein expression (Fig.5D). In parallel to the 2.2-fold and 3.6-fold TCF7L2 down-regulation by 11.1 mM glucose or IL-1β+IFN-γ, cleaved caspase-3 expression was 1.5-fold induced. In islets over-expressing TCF7L2, its protein expression levels were 1.5-fold, 2.4-fold and 3.4-fold induced at 5.5, 11.1 mM glucose or 5.5 mM glucose plus IL-1β+IFN-γ, compared to the empty vector treated control, respectively (Fig.5D,E; $p<0.05$) and mRNA levels were 416-fold, 394-fold and 705-fold increased, respectively ($p<0.01$; data not shown). In contrast, caspase-3 was activated by glucose and IL-1β+IFN-γ, and TCF7L2 reversed such up-regulation. Even at control incubations, the signal for caspase-3, which is mostly seen in isolated human islets, was down-regulated by TCF7L2 over-expression, indicating an overall protection from β-cell apoptosis by TCF7L2.

DISCUSSION

The identification of single nucleotide polymorphisms (SNPs) in the transcription factor-7–like 2 (*TCF7L2*) gene and its strong association with T2DM as well as with impaired insulin secretion (4-13) is an essential breakthrough in the field of genetics of T2DM.

Our study provides further evidence that TCF7L2 is an important regulator of β-cell function and survival. Chronic hyperglycemia and the cytokine mixture with IL-1β plus IFN-γ decreased TCF7L2 expression in the islets. In turn, TCF7L2 over-expression protected from the effects of chronically elevated glucose and cytokines on β-cell apoptosis and function. In vitro, TCF7L2 depletion in islets reduced proliferation, induced β-cell apoptosis and decreased glucose stimulated insulin secretion. During islet perifusion, insulin secretion in response to glucose was delayed and impaired in TCF7L2 depleted islets. Interestingly, GLP-1 increased glucose stimulated insulin secretion in control islets to much greater extent than in TCF7L2 depleted islets. These data are in line with a recent study in human patients, which shows that carriers of the TCF7L2 risk allele showed a significant reduction in GLP-1-induced insulin secretion, without defects in GLP-1 secretion during an OGTT (27). This supports the hypothesis that changes in TCF7L2 result in a functional defect of GLP-1 signaling in β-

cells and may explain the impaired insulin secretion in carriers of the TCF7L2 risk alleles and the increased risk of T2DM. Cell membrane depolarization by addition of 20 mM KCl raised insulin secretion in both, control and TCF7L2 depleted islets. Although the absolute KCl stimulated insulin secretion was much higher in control islets, the relative increase in insulin levels in response to KCl was comparable in both groups. Calculation of the average stimulatory index in islets in response to KCl showed no differences in control and TCF7L2 depleted islets. One important mechanism of the potentiation of glucose stimulated insulin secretion by GLP-1 is the increase in the number of insulin secretory granules which dock to the β-cell membrane during stimulation (28). GLP-1 significantly increases the maximum insulin secretion induced by glucose and by KCl (29). Therefore we hypothesize that defective GLP-1 signaling observed in our study is responsible for the observed impaired absolute KCl induced insulin response.

The protective effect of TCF7L2 over-expression on impaired β-cell function induced by glucotoxicity and cytokine toxicity was mainly a result of a decreased basal insulin secretion. Apoptotic cells have often increased basal insulin levels during the 1-hour static incubation, as a result of dying cells, which release their insulin. Especially under conditions of chronic hyperglycemia basal insulin release is increased (30). These data provide further evidence of the important role of TCF7L2 on β-cell survival.

It has been recognized in the past, that isolated islets themselves are highly susceptible to β-cell apoptosis, whereas *in vivo*, only very few apoptotic cells can be found in pancreatic sections. For analysis of β-cell proliferation in this study, we used islets from young human islet donors (24 and 41 years), and therefore observed a relatively high number of proliferating cells, when we plated the islets on extracellular matrix-coated dishes, with the majority being β-cells detected by double staining for Ki67 and insulin. This culture condition allows us to study long-term islet survival and function and we also detect some β-cell proliferation (17), whereas *in vivo*, β-cell proliferation in adult human islets is very limited. Using the same culture conditions, we have recently shown that there is an age-dependent decline in β-cell proliferation (31), which was in consistency with a study by Butler et al. (3) using pancreatic sections from autopsy.

One important regulator of β-cell survival is the protein kinase B /AKT pathway. Also the anti-apoptotic mechanism of GLP-1 is mediated through AKT (32). AKT activation has been reported to mediate survival of isolated human islets through insulin in an autocrine manner (33). Reduced AKT activity has also been associated with defective insulin secretion (34). Moreover, impaired AKT activation was associated with reduced GSK-3 inactivation (35), a gene associated with increased β-cell apoptosis (36) and compound in the WNT signaling pathway, which degrades β-catenin, and thus restricting nuclear activation of TCF7L2 i(37). Almost undetectable p-AKT in the TCF7L2 depleted islets therefore may explain the deleterious effects of loss of TCF7L2 on both β-cell survival and insulin secretion.

TCF7L2 is expressed in isolated human islets, shown by Western Blot analysis, RT-PCR and immunostaining. This is in line with recent results from human islets (10; 38) and from Zucker diabetic fatty rat islets and their lean controls. In contrast, TCF7L2 was not detectable in mouse pancreatic sections and in the pancreatic InR1-G9 cell line (15).

In our study we have observed that treatment of isolated islets with siRNA to TCF7L2 resulted in decreased TCF7L2 mRNA and protein expression and induced impaired β-cell survival and function. In contrast, TCF7L2 mRNA is increased in islets isolated from the Zucker diabetic fatty (ZDF) rat (38) as well as from patients with T2DM (12). Also, in individuals carrying an increased number of TCF7L2 risk T-alleles, TCF7L2 mRNA expression levels are increased (12). Both studies did not investigate TCF7L2 protein levels. Since we observed that increased TCF7L2 protein had protective effects on β-cell survival, we hypothesize that the posttranscriptional

regulation of TCF7L2 rather than changes in mRNA levels may alter the β-cell.

TCF7L2 mRNA expression was also analyzed in muscle, fat and lymphocytes in correlation with TCF7L2 variants. In transformed lymphocytes TCF7L2 was differently regulated in controls and patients with T2DM, in control individuals TCF7L2 mRNA expression decreased with the number of T-alleles whereas in T2DM it increased. Interestingly, no changes were observed in muscle or fat tissue (39), although TCF7L2 expression in adipose tissue is decreased in obese individuals with T2DM (10).

In this study, we report that elevated glucose levels and cytokine in cultured islets decreased TCF7L2 mRNA and protein levels. Therefore, further *in vivo* studies are needed using TCF7L2 variants in mice to confirm these results and translate them into the pathophysiology of T2DM.

Our data show, that regulation of TCF7L2 plays an important role in the regulation of both, β-cell survival and function and that targeting its expression could be a new strategy to maintain β-cell survival in diabetes.

ACKNOWLEDGEMENTS

This work was supported by the American Diabetes Association (Junior Faculty Grant 706JF41) and the Larry L. Hillblom Research Foundation (LLHF grant No. 2005 1C). Nadine S Sauter and Fabienne T Schulthess are recipients of the Swiss National Foundation Fellowship award.

Human islets were provided through the Islet Cell Resource Consortium, administered by the ABCC and supported by NCRR, NIDDK and JDRF.

We thank Lendy N. Le for excellent technical assistance and colleagues at the Larry Hillblom Islet Center at UCLA, especially Drs. Peter Butler and Leena Haataja for helpful discussion.

REFERENCES

1. Buchanan TA: Pancreatic beta-cell loss and preservation in type 2 diabetes. *Clin Ther* 25 Suppl B:B32-46, 2003
2. Robertson RP: Type II diabetes, glucose "non-sense," and islet desensitization. *Diabetes* 38:1501-1505, 1989
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* 52:102-110, 2003
4. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. *Nat Genet* 38:320-323, 2006
5. Freathy RM, Weedon MN, Bennett A, Hypponen E, Relton CL, Knight B, Shields B, Parnell KS, Groves CJ, Ring SM, Pembrey ME, Ben-Shlomo Y, Strachan DP, Power C, Jarvelin MR, McCarthy MI, Davey Smith G, Hattersley AT, Frayling TM: Type 2 diabetes TCF7L2 risk genotypes alter birth weight: a study of 24,053 individuals. *Am J Hum Genet* 80:1150-1161, 2007
6. Groves CJ, Zeggini E, Minton J, Frayling TM, Weedon MN, Rayner NW, Hitman GA, Walker M, Wiltshire S, Hattersley AT, McCarthy MI: Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. *Diabetes* 55:2640-2644, 2006
7. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. *N Engl J Med* 355:241-250, 2006
8. Saxena R, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjogren M, Florez JC, Almgren P, Isomaa B, Orho-Melander M, Lindblad U, Daly MJ, Tuomi T, Hirschhorn JN, Ardlie KG, Groop LC, Altshuler D: Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. *Diabetes* 55:2890-2895, 2006
9. Zhang C, Qi L, Hunter DJ, Meigs JB, Manson JE, van Dam RM, Hu FB: Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. *Diabetes* 55:2645-2648, 2006
10. Cauchi S, Meyre D, Dina C, Choquet H, Samson C, Gallina S, Balkau B, Charpentier G, Pattou F, Stetsyuk V, Scharfmann R, Staels B, Fruhbeck G, Froguel P: Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. *Diabetes* 55:2903-2908, 2006
11. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 316:1341-1345, 2007
12. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, Sjogren M, Ling C, Eriksson KF, Lethagen UL, Mancarella R, Berglund G, Tuomi T, Nilsson P, Del Prato S, Groop L: Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. *J Clin Invest* 117:2155-2163, 2007

13. Florez JC: The new type 2 diabetes gene TCF7L2. *Curr Opin Clin Nutr Metab Care* 10:391-396, 2007
14. Smith U: TCF7L2 and type 2 diabetes-we WNT to know. *Diabetologia* 50:5-7, 2007
15. Yi F, Brubaker PL, Jin T: TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. *J Biol Chem* 280:1457-1464, 2005
16. Oberholzer J, Triponez F, Mage R, Andereggen E, Buhler L, Cretin N, Fournier B, Goumaz C, Lou J, Philippe J, Morel P: Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations. *Transplantation* 69:1115-1123, 2000
17. Kaiser N, Corcos AP, Sarel I, Cerasi E: Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of B-cell function by chronic exposure to high glucose. *Endocrinology* 129:2067-2076, 1991
18. Schumann DM, Maedler K, Franklin I, Konrad D, Storling J, Boni-Schnetzler M, Gjinovci A, Kurrer MO, Gauthier BR, Bosco D, Andres A, Berney T, Greter M, Becher B, Chervonsky AV, Halban PA, Mandrup-Poulsen T, Wollheim CB, Donath MY: The Fas pathway is involved in pancreatic {beta} cell secretory function. *Proc Natl Acad Sci U S A* 104:2861-2866, 2007
19. Ling Z, Kiekens R, Mahler T, Schuit FC, Pipeleers-Marichal M, Sener A, Kloppel G, Malaisse WJ, Pipeleers DG: Effects of chronically elevated glucose levels on the functional properties of rat pancreatic beta-cells. *Diabetes* 45:1774-1782, 1996
20. Topp B, Promislow K, deVries G, Miura RM, Finegood DT: A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes. *J Theor Biol* 206:605-619, 2000
21. Efanova IB, Zaitsev SV, Zhivotovsky B, Kohler M, Efendic S, Orrenius S, Berggren PO: Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. *J Biol Chem* 273:33501-33507, 1998
22. Maedler K, Storling J, Sturis J, Zuellig RA, Spinas GA, Arkhammar PO, Mandrup-Poulsen T, Donath MY: Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. *Diabetes* 53:1706-1713, 2004
23. Maedler K, Schumann DM, Sauter N, Ellingsgaard H, Bosco D, Baertschiger R, Iwakura Y, Oberholzer J, Wollheim CB, Gauthier BR, Donath MY: Low Concentration of Interleukin-1{beta} Induces FLICE-Inhibitory Protein-Mediated {beta}-Cell Proliferation in Human Pancreatic Islets. *Diabetes* 55:2713-2722, 2006
24. Song SH, Kjems L, Ritzel R, McIntyre SM, Johnson ML, Veldhuis JD, Butler PC: Pulsatile insulin secretion by human pancreatic islets. *J Clin Endocrinol Metab* 87:213-221, 2002
25. Rhodes CJ: Type 2 diabetes-a matter of beta-cell life and death? *Science* 307:380-384, 2005
26. Maedler K: Beta cells in type 2 diabetes - a crucial contribution to pathogenesis. *Diabetes Obes Metab*, 2007
27. Schafer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, Holst JJ, Dekker JM, T'Hart L M, Nijpels G, van Haeften TW, Haring HU, Fritsche A: Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. *Diabetologia*, 2007
28. Kwan EP, Gaisano HY: Glucagon-like peptide 1 regulates sequential and compound exocytosis in pancreatic islet beta-cells. *Diabetes* 54:2734-2743, 2005
29. Montrose-Rafizadeh C, Egan JM, Roth J: Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action. *Endocrinology* 135:589-594, 1994
30. Kaiser N, Leibowitz G, Nesher R: Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. *J Pediatr Endocrinol Metab* 16:5-22, 2003
31. Maedler K, Schumann DM, Schulthess F, Oberholzer J, Bosco D, Berney T, Donath MY: Aging correlates with decreased beta-cell proliferative capacity and enhanced sensitivity to

apoptosis: a potential role for Fas and pancreatic duodenal homeobox-1. *Diabetes* 55:2455-2462, 2006
32. Li L, El-Kholy W, Rhodes CJ, Brubaker PL: Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. *Diabetologia* 48:1339-1349, 2005
33. Aikin R, Hanley S, Maysinger D, Lipsett M, Castellarin M, Paraskevas S, Rosenberg L: Autocrine insulin action activates Akt and increases survival of isolated human islets. *Diabetologia* 49:2900-2909, 2006
34. Bernal-Mizrachi E, Fatrai S, Johnson JD, Ohsugi M, Otani K, Han Z, Polonsky KS, Permutt MA: Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. *J Clin Invest* 114:928-936, 2004
35. D'Alessandris C, Andreozzi F, Federici M, Cardellini M, Brunetti A, Ranalli M, Del Guerra S, Lauro D, Del Prato S, Marchetti P, Lauro R, Sesti G: Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells. *Faseb J* 18:959-961, 2004
36. Srinivasan S, Ohsugi M, Liu Z, Fatrai S, Bernal-Mizrachi E, Permutt MA: Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells. *Diabetes* 54:968-975, 2005
37. Katoh M: WNT2B: comparative integromics and clinical applications (Review). *Int J Mol Med* 16:1103-1108, 2005
38. Parton LE, McMillen PJ, Shen Y, Docherty E, Sharpe E, Diraison F, Briscoe CP, Rutter GA: Limited role for SREBP-1c in defective glucose-induced insulin secretion from Zucker diabetic fatty rat islets: a functional and gene profiling analysis. *Am J Physiol Endocrinol Metab* 291:E982-994, 2006
39. Elbein SC, Chu WS, Das SK, Yao-Borengasser A, Hasstedt SJ, Wang H, Rasouli N, Kern PA: Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. *Diabetologia* 50:1621-1630, 2007

FIGURE LEGENDS

Figure 1. TCF7L2 is expressed in the β-cell and its depletion results in impaired β-cell function

(A) Isolated human islets were cultured on extracellular matrix-coated dishes and transfected with either an empty control plasmid (1), pCMV-TCF7L2 (2) or siRNA to TCF7L2 (3) for 4 days, fixed and triple-stained for TCF7L2 in red, DAPI in blue and insulin in green. For evaluating transfection efficiency, islets were transfected with an FITC labeled non-targeted siRNA and transfection was analyzed under the fluorescent microscope after 24 (4) and 48 hours (5).
Isolated mouse **(B,C)** and human **(D,E,F)** pancreatic islets were cultured on extracellular matrix-coated dishes and exposed to three different siRNA sequences to TCF7L2 (siTCF7L2-1,-2,-3) or scrambled control siRNA (siScr) for 4 days.
(B,D) Basal and stimulated insulin secretion indicate the amount secreted during 1-hour incubations at 2.8 (basal) and 16.7 mM (stimulated) glucose following the 4-day culture period, normalized to whole islet protein content. **(C,E)** Stimulatory index, which denotes the amount of stimulated divided by the amount of basal insulin secretion. **(F)** Quantitative RT-PCR analysis of TCF7L2, insulin and PDX-1 expression. The levels of mRNA expression were normalized against β-actin and tubulin with similar results and shown as change from control (siScr). Data represent results of two independent experiments from two different organ donors in quadruplicate (human) or from two independent experiments from mouse islets (n=8). Results are means ± SE of scrambled siRNA treated controls at 5.5 mM (human islets) or 11.1 mM (mouse islets) glucose, *p<0.05 to scrambled control.

Figure 2. Loss of TCF7L2 results in impaired glucose and GLP-1 stimulated insulin secretion

Human islets transfected with scrambled control (siScr) or TCF7L2 siRNA (siTCF7L2-2) were placed in perifusion chambers in aliquots of 20 of equal size. The perifusate contained 2.8 mM glucose for 1h, 16.7 mM glucose for 40 min., 16.7 mM glucose and 100 nM GLP-1 for 30 min., 2.8 mM glucose for 30 min. (the effluent was collected in 5-min intervals) and 10 min 20 mM KCl (the effluent was collected in 2-min intervals). Insulin secretion is expressed as percentage of content. One experiment was performed in triplicate from one organ donor. A and B show results from the same experiment with different y-axes scale to visualize changes in glucose stimulated insulin secretion. *p<0.05 to siScr control

Figure 3. Depletion in TCF7L2 results in impaired β-cell turnover

Isolated human pancreatic islets were cultured on extracellular matrix-coated dishes and exposed to two different siRNA sequences to TCF7L2 (siTCF7L2-1,-2) or scrambled control siRNA (siScr) for 4 days. Proliferation was measured by the Ki67 antibody **(A,C-upper panel)** stained in red (cy3) and apoptosis by the TUNEL assay (**B,C-lower panel**) and stained in black (alkaline phosphate). Islets were triple-stained for insulin in green **(C-upper panel)** and counterstained for DAPI in blue (not shown). White arrows point to proliferating and apoptotic β-cells. The insert of higher magnification shows a proliferating β-cell.
Results are means ± SE of the percentage of Ki67 positive **(A)** TUNEL-positive **(B)** or β-cells normalized to control incubations (siScr) at 5.5 mM glucose alone (100%; in absolute value: 0.29% TUNEL-positive and 1.78% Ki67-positive β-cells). The average number of β-cells counted were 26,130 for each treatment group in each of the two separate experiments from two different organ donors in quadruplicate (n=8).
(D) Western blot analysis of TCF7L2, cleaved Caspase-3, cleaved PARP and Actin and p-AKT **(F)** and Actin in human islets exposed for 4 days to siScr or siTCF7L2. Actin was used as a loading control on the same membrane after stripping. Blot is representative of three

independent experiments from three different organ donors. **(E)** The density of expression levels were quantified after scanning, normalised to actin levels and expressed as change from siScr control, respectively. *p<0.05 to untreated control.

Figure 4. Overexpression of TCF7L2 protects from glucotoxicity and cytokine toxicity
Isolated mouse **(A,B)** and human **(C,D)** pancreatic islets were cultured on extracellular matrix-coated dishes and exposed to increasing glucose concentrations (5.5, 11.1, 33.3 mM) or the mixture of IL-1β+IFN-γ (ILIF) and transfected with either pCMV-TCF7L2 or an empty control plasmid under the same promoter.
(A,C) Basal and stimulated insulin secretion indicate the amount secreted during 1-hour incubations at 2.8 (basal) and 16.7 mM (stimulated) glucose following the 4-day culture period, normalized to whole islet protein content. **(B,D)** Stimulatory index, which denotes the amount of stimulated divided by the amount of basal insulin secretion. Data represent results of two different experiments from two different organ donors in quadruplicate (human) or of two independent experiments from mouse islets (n=8). Results are means ± SE of empty vector treated control islets at 5.5 mM (human islets) or 11.1 mM (mouse islets) glucose, *p<0.05 to untreated control, +p<0.05 to empty vector transfected islets at same treatment.

Figure 5. Overexpression of TCF7L2 protects from glucose- and cytokine- induced β-cell apoptosis and decreased proliferation
Isolated human pancreatic islets were cultured on extracellular matrix-coated dishes and exposed to increasing glucose concentrations (5.5, 11.1, 33.3 mM) or the mixture of IL-1β+IFN-γ (ILIF) and transfected with either pCMV-TCF7L2 or an empty control plasmid under the same promoter.
Proliferation was measured by the Ki67 antibody **(A,C-upper panel)** stained in red (cy3) and apoptosis by the TUNEL assay (**B,C-lower panel**) and stained in black (alkaline phosphate). Islets were triple-stained for insulin in green **(C-upper panel)** and counterstained for Dapi in blue (not shown). White arrows point to proliferating and apoptotic β-cells. The insert of higher magnification shows a proliferating β-cell.
Results are means ± SE of the percentage of Ki67 positive **(A)** TUNEL-positive **(B)** or β-cells normalized to control incubations (pCMV-empty) at 5.5 mM glucose alone (100%; in absolute value: 0.33% TUNEL-positive and 2.09% Ki-67-positive β-cells). The average number of β-cells counted were 20,630 for each treatment group in each of the two separate experiments from two different organ donors in quadruplicate (n=8).
(D) Western blot analysis of TCF7L2, cleaved Caspase-3 and Actin in human islets exposed for four days to 5.5 or 11.1 mM glucose or 5.5 mM plus IL-1β+IFN-γ. Islets were transfected with a CMV-TCF7L2 plasmid or an empty control plasmid using the same promoter (pCMV-empty). Actin was used as a loading control on the same membrane after stripping. Blot is representative of three independent experiments from three different organ donors. **(E)** The density of expression levels were quantified after scanning, normalised to actin levels and expressed as change from control (5.5 mM glucose). *p<0.05 to untreated control, +p<0.05 to empty vector transfected islets at same treatment.

FIGURE 1


A
DAPI/TCF7L2/insulin 1
empty Vector
DAPI/TCF7L2/insulin 2
TCF7L2-OE
DAPI/TCF7L2/insulin 3
TCF7L2-2-siRNA
FITC-labeled siRNA-24h
FITC-labeled siRNA-48h
mouse islets
B
insulin secretion ng/mg protein/h
basal
stimulated
siScr
siTCF7L2 1-3
C
stimulatory index
siScr
siTCF7L2-1
siTCF7L2-2
siTCF7L2-3
treatment
human islets
D
insulin secretion ng/mg protein/h
basal
stimulated
siScr
siTCF7L2-2
E
stimulatory index
siScr
siTCF7L2-2
treatment
human islets
F
mRNA/tubulin
siScr
siTCF7L2-2
TCF7L2
insulin
PDX-1

FIGURE 2


A
2.8 mM
16.7 mM
2.8 mM
GLP-1
KCl
insulin (% of content)
siScr
siTCF7L2
n.s.
min 0
30
60
90
120.....130
B
2.8 mM
16.7 mM
siScr
siTCF7L2
n.s.
insulin (% of content)
min 0
30
60

FIGURE 3


A
siScr
siTCF7L2-1
siTCF7L2-2
Ki67+ β-cells/ % of control
125
100
75
50
25
0
5.5 mM glucose
B
TUNEL+ β-cells/ % of control
600
500
400
300
200
100
0
5.5 mM glucose
C
siScr
siTCF7L2-2
Ki67/insulin
TUNEL
D
siScr
siTCF7L2-2
TCF7L2
58 kDa
cleaved Casp3
17 kDa
cleaved PARP
89 kDa
Actin
42 kDa
E
siScr
siTCF7L2 -2
protein/Actin
compared to control
5
0
TCF7L2 PARP Casp3
F
siScr
siTCF7L2-1
siTCF7L2-2
p-AKT
(Ser473)
60 kDa
Actin
42 kDa

FIGURE 4


mouse
A
insulin secretion ng/mg protein/h
basal
stim
glucose (mM) 11.1 11.1 33.3 33.3 11.1+ILIF
pCMV-TCF7L2 + + +
B
stimulatory index
EMPTY
TCF7L2
11.1 33.3 11.1+ILIF
human
C
insulin secretion ng/mg protein/h
basal
stim
glucose (mM) 5.5 5.5 11.1 11.1 33.3 33.3 5.5+ILIF
pCMV-TCF7L2 + + +
D
stimulatory index
EMPTY
TCF7L2
5.5 11.1 33.3 5.5+ILIF

FIGURE 5


A
Ki67+ β-cells/ % of control
125
100
75
50
25
0
EMPTY
TCF7L2
5.5
11.1
33.3
5.5+ILIF
B
TUNEL+β-cells/% of control
300
250
200
150
100
50
0
EMPTY
TCF7L2
5.5
11.1
33.3
5.5+ILIF
C
control 5.5 mM
11.1 mM
11.1 mM+TCF7L2
ILIF
ILIF+TCF7L2
Ki67/insulin
TUNEL
D
5.5
11.1
5.5+ILIF
5.5
11.1
5.5+ILIF
TCF7L2
58 kDa
cleaved Casp3
17 kDa
Actin
42 kDa
transfection:
empty control
TCF7L2
E
EMPTY
TCF7L2
TCF7L2/Actin compared to control
1.5
1.0
0.5
0.0
5.5
11.1
5.5+ILIF
Caspase3/Actin compared to control
2.0
1.5
1.0
0.5
0.0
5.5
11.1
5.5+ILIF